ProFecund: clinical trial

ProFecund has been sumitted to a clinical trial, in order to assess its efficacy with certainty.

The chosen variant was that of a prospective interventional multicentre national study.

The study was conducted over a period of 18 months, from June 2016 to December 2017.

The term “multicentre national study” means that it was conducted simultaneously in nine national centres, under the supervision of eleven gynaecology and endocrinology specialists.

“Prospective interventional” means that the 189 participating women, with known fertility problems, were treated with ProFecund and monitored by their doctors throughout the administration of the drug.

The patients were divided into two groups. The 103 women in the first group received one ProFecund tablet daily. For those in the second group, the treatment was supplemented daily with one tablet and one capsule of NatalVit IQ (a multivitamin and mineral complex, plus DHA and EPA, two essential fatty acids).

The treatments lasted up to six months (they were discontinued if the patient got pregnant). During this time, their partners received one capsule of ProFecund B every day.

The results of the study were more than promising:

Out of 189 patients, 70 got pregnant

The success rate was therefore 37% or, in other words, more than one in three patients got pregnant. The chart below shows this success rate.

Evolution of the number of pregnancies in relation to the number of months of treatment.